ClinicalTrials.Veeva

Menu
The trial is taking place at:
P

Panax Clinical Research | Miami Lakes, FL

Veeva-enabled site

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)

Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

Status and phase

Enrolling
Phase 3

Conditions

Severe Hypertriglyceridemia

Treatments

Drug: Plozasiran Injection
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06347003
AROAPOC3-3003
2023-509300-14 (EudraCT Number)

Details and patient eligibility

About

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Enrollment

405 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Established diagnosis of severe hypertriglyceridemia (SHTG) and prior documented evidence (medical history) of fasting TG levels of ≥ 500 mg/dL (≥5.65mmol/L)
  • Mean fasting TG level ≥500 mg/dL (≥5.65 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
  • Fasting low density lipoprotein-cholesterol (LDL-C) ≤130 mg/dL (≤3.37 mmol/L) at screening
  • Screening HbA1C ≤8.5%
  • Willing to follow diet counseling and maintain a stable low-fat diet
  • Must be on standard of care lipid-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator)

Exclusion criteria

  • Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of investigational drug and inclisiran must be separated by at least 4 weeks
  • Use of any other hepatocyte-targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer
  • Known diagnosis of familial chylomicronemia syndrome (FCS) (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote or double heterozygote for loss-of-function mutations in type 1-causing genes
  • Acute pancreatitis within 4 weeks prior to screening
  • Body mass index >45kg/m^2

Note: Additional Inclusion/Exclusion criteria may apply per protocol

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

405 participants in 2 patient groups, including a placebo group

Plozasiran Injection
Experimental group
Description:
4 doses of plozasiran (ARO-APOC3) by subcutaneous (sc) injection
Treatment:
Drug: Plozasiran Injection
Placebo
Placebo Comparator group
Description:
calculated volume to match active treatment by sc injection
Treatment:
Drug: Placebo

Trial contacts and locations

41

Loading...

Central trial contact

Medical Monitor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems